June 27, 2024
Weight management concerns - including the potential use of GLP-1 medications - should be evaluated by a licensed clinician
Semaglutide The first GLP1-receptor agonist to be made available both orally and by subcutaneous injection was semaglutide
Currently enrolled in phase 2 clinical trials, MariTide is expected to conclude by late 2024, with future studies in phase 3 focusing on obesity and its associated conditions, including heart, liver, and kidney diseases
Rodbard HW, Rosenstock J, Canani LH, et al
Either way, run the numbers through the reconstitution calculator with the corrected water volume, and your new units per dose will be accurate